Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.

1/10 Last #NephJC we discussed pegcetacoplan in C3 glomerulopathy and Immune-Complex MPGN #TenPostNephJC

Given the central role of complement dysregulation in C3GN, the 🔑 question was whether 🎯 complement inhibition could deliver clinical benefithttps://t.co/1GyC3P8emi pic.twitter.com/Hllq7tEJaG
— Nephrology Journal Club (@NephJC) January 16, 2026